It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CHGCF’s FA Score shows that 0 FA rating(s) are green whileCMOPF’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CHGCF’s TA Score shows that 3 TA indicator(s) are bullish while CMOPF’s TA Score has 4 bullish TA indicator(s).
CHGCF (@Pharmaceuticals: Major) experienced а -14.25% price change this week, while CMOPF (@Pharmaceuticals: Major) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.19%. For the same industry, the average monthly price growth was +2.56%, and the average quarterly price growth was +9.33%.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
CHGCF | CMOPF | CHGCF / CMOPF | |
Capitalization | 49.4B | 828M | 5,966% |
EBITDA | 458B | 42.1M | 1,087,886% |
Gain YTD | 11.886 | -3.818 | -311% |
P/E Ratio | 20.79 | 68.49 | 30% |
Revenue | 1.24T | 104M | 1,196,154% |
Total Cash | 665B | 222M | 299,550% |
Total Debt | 215M | 176M | 122% |
CHGCF | CMOPF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 83 | 100 | |
SMR RATING 1..100 | 41 | 89 | |
PRICE GROWTH RATING 1..100 | 54 | 61 | |
P/E GROWTH RATING 1..100 | 65 | 97 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CMOPF's Valuation (15) in the null industry is somewhat better than the same rating for CHGCF (74). This means that CMOPF’s stock grew somewhat faster than CHGCF’s over the last 12 months.
CHGCF's Profit vs Risk Rating (83) in the null industry is in the same range as CMOPF (100). This means that CHGCF’s stock grew similarly to CMOPF’s over the last 12 months.
CHGCF's SMR Rating (41) in the null industry is somewhat better than the same rating for CMOPF (89). This means that CHGCF’s stock grew somewhat faster than CMOPF’s over the last 12 months.
CHGCF's Price Growth Rating (54) in the null industry is in the same range as CMOPF (61). This means that CHGCF’s stock grew similarly to CMOPF’s over the last 12 months.
CHGCF's P/E Growth Rating (65) in the null industry is in the same range as CMOPF (97). This means that CHGCF’s stock grew similarly to CMOPF’s over the last 12 months.
CHGCF | CMOPF | |
---|---|---|
RSI ODDS (%) | N/A | 6 days ago38% |
Stochastic ODDS (%) | 3 days ago54% | 3 days ago20% |
Momentum ODDS (%) | 3 days ago56% | N/A |
MACD ODDS (%) | 3 days ago47% | 3 days ago6% |
TrendWeek ODDS (%) | 3 days ago49% | 3 days ago23% |
TrendMonth ODDS (%) | 3 days ago34% | 3 days ago23% |
Advances ODDS (%) | 10 days ago60% | N/A |
Declines ODDS (%) | 6 days ago70% | N/A |
BollingerBands ODDS (%) | 3 days ago27% | N/A |
Aroon ODDS (%) | 3 days ago41% | 3 days ago25% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MLRRX | 12.23 | 0.15 | +1.24% |
NYLI Winslow Large Cap Growth Class R1 | |||
JIISX | 82.19 | 0.70 | +0.86% |
JPMorgan US Sustainable Leaders I | |||
PORIX | 60.58 | 0.36 | +0.60% |
Trillium ESG Global Equity Institutional | |||
FIJDX | 38.85 | 0.22 | +0.57% |
Fidelity Advisor Gold Z | |||
UEIPX | 14.47 | 0.06 | +0.42% |
UBS Engage For Impact P |
A.I.dvisor tells us that CHGCF and CHGCY have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CHGCF and CHGCY's prices will move in lockstep.
Ticker / NAME | Correlation To CHGCF | 1D Price Change % | ||
---|---|---|---|---|
CHGCF | 100% | -9.99% | ||
CHGCY - CHGCF | 32% Poorly correlated | -0.89% | ||
CMOPF - CHGCF | 10% Poorly correlated | N/A | ||
DSKYF - CHGCF | -2% Poorly correlated | -2.39% | ||
CHJTF - CHGCF | -3% Poorly correlated | N/A | ||
DSNKY - CHGCF | -5% Poorly correlated | -2.41% | ||
More |
A.I.dvisor tells us that CMOPF and CHGCF have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and CHGCF's prices will move in lockstep.
Ticker / NAME | Correlation To CMOPF | 1D Price Change % | ||
---|---|---|---|---|
CMOPF | 100% | N/A | ||
CHGCF - CMOPF | 10% Poorly correlated | -9.99% | ||
CHGCY - CMOPF | 5% Poorly correlated | -0.89% | ||
BAYZF - CMOPF | 2% Poorly correlated | -0.90% | ||
GIFLF - CMOPF | 1% Poorly correlated | N/A | ||
CHJTF - CMOPF | -0% Poorly correlated | N/A | ||
More |